Fennec Pharmaceuticals Inc. FENC R2K

Q: What is the current share price of Fennec Pharmaceuticals Inc. (FENC)?

As of 2026-07-15 16:51 PDT, Fennec Pharmaceuticals Inc. (FENC) trades at $10.60 on NasdaqCM. Its 52-week range is $5.77 to $11.16.

Q: What is the market capitalisation of FENC?

Fennec Pharmaceuticals Inc. (FENC) has a market capitalisation of $368.21M on NasdaqCM.

Q: What is the P/E ratio of FENC?

FENC trades at a trailing price-to-earnings (P/E) ratio of -35.33. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 10.23.

Q: What is the return on equity (ROE) of FENC?

FENC has a return on equity (ROE) of -52.68%. Its return on capital employed (ROCE) is -10.46%.

Q: Is FENC a good stock to buy?

This page provides a data-driven analysis of Fennec Pharmaceuticals Inc. (FENC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.fennecpharma.com

Company Profile ↓

$10.60

+20.59% 1Y

Mkt Cap$368.21M

P/E-35.33

P/B10.23

52W High$11.16

52W Low$5.77

Book Value$1.09

EPS (TTM)$-0.30

Company Overview

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Recent Developments

Dec 2025 Revenue of $44.64M (-6.1% YoY); net profit $-9.74M.
Trailing 12 Months Year-on-year growth — revenue +72.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-
1 Year:	72.60%

Stock Price Performance

1 Year:	+20.59%
6 Months:	+39.11%
3 Months:	+69.60%
1 Month:	+17.78%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 90% of range

$5.77 $11.16

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)57.42 · Neutral

Price Performance

1M+17.78%

3M+69.60%

6M+39.11%

1Y+20.59%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-35.33

Industry PE

25.88

Forward P/E

11.91

PEG Ratio

1.47

Book Value

$1.09

Price to Book

10.23

P/S

7.60

EV/EBITDA

-63.29

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

Revenue (YoY)

72.60%

Earnings (YoY)

Profitability & Returns

ROCE

-10.46%

ROE

-52.68%

ROA

-5.91%

Profit Margin

-16.42%

Op Margin

-0.79%

Gross Margin

92.23%

EPS (Latest Qtr)

$0.01

EPS (TTM)

$-0.30

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

6.15

Current Ratio

6.98

Debt

Total Assets

$71.82M

Current Assets

Working Capital

Ownership

Promoter Holding

14.46%

Chg in Prom Hold

0.00%

FII / Inst Holding

54.29%

Chg in FII Hold

0.00%

Financial Snapshot

Enterprise Value

$368.21M

Total Revenue (TTM)

$51.00M

EBITDA

$-5.49M

Free Cash Flow

$-2.37M

Operating Cash Flow

$-5.78M

Shares Outstanding

34.74M

Gross Margin

92.23%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	FENC Fennec Pharmaceuticals Inc. R2K	10.60	-35.33	$368.21M	0.00%	-10.46%	-52.68%	-	-
2	LLY Eli Lilly and Company SPX	1,156.63	41.13	$1.03T	0.60%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	247.02	28.66	$594.63B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.11	119.08	$431.29B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	418.52	31.54	$380.08B	2.18%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	123.61	34.82	$305.29B	2.82%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	168.37	26.10	$261.12B	1.87%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	535.29	29.40	$198.93B	0.35%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	358.32	24.92	$193.39B	2.80%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	0	0	0	0	0	0	0	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	1.68M	3.33M	6.51M	25.38M	7.26M	6.97M	8.75M	9.65M	12.46M	15.11M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.58M	3.18M	6.18M	-	-	-	-	-	-	-
Operating Income	-51.00K	-537.00K	-930.00K	-619.00K	-452.00K	-549.00K	-338.00K	-	-454.00K	-707.00K	-564.00K	-	-771.00K	-1.48M	-2.19M	-1.79M	-2.67M	-2.85M	-2.68M	-4.81M	-1.86M	-3.83M	-4.84M	-5.86M	-4.92M	-3.92M	-4.17M	-3.55M	-5.01M	-7.90M	-5.27M	-4.67M	-1.02M	13.74M	-5.04M	-5.20M	-808.00K	-2.73M	-189.00K	-119.00K
Net Income	-1.77M	-3.19M	-750.00K	380.00K	177.00K	-173.00K	-123.00K	-540.00K	-420.00K	-724.00K	-502.00K	-1.14M	-806.00K	-1.60M	-2.35M	-1.57M	-2.59M	-2.75M	-2.63M	-4.73M	-1.81M	-3.83M	-4.84M	-6.20M	-4.73M	-4.00M	-4.18M	-3.70M	-5.07M	-8.09M	-6.05M	-5.44M	-1.87M	12.84M	-5.55M	-5.74M	-1.17M	-3.15M	-638.00K	201.00K
Diluted EPS	-	-0.33	-0.08	0.03	0.01	-0.02	-0.01	-	-0.04	-0.06	-0.04	-	-0.06	-0.11	-0.15	-0.09	-0.14	-0.14	0.14	-0.24	-0.09	-0.19	-0.21	-0.24	-0.18	-0.15	-0.16	-0.14	-0.19	-0.31	-0.23	-0.21	-0.07	0.41	-0.20	-0.21	-0.04	-0.11	-0.02	0.01
R&D Expense	-	-	72.00K	88.00K	43.00K	54.00K	88.00K	-	47.00K	139.00K	112.00K	-	225.00K	333.00K	492.00K	689.00K	798.00K	1.80M	1.67M	1.97M	795.00K	1.39M	1.12M	1.37M	2.42M	800.00K	1.24M	1.44M	1.13M	846.00K	4.00K	8.00K	12.00K	3.00K	157.00K	97.00K	94.00K	107.00K	29.00K	49.00K

Profit & Loss (Annual)

Figures in USD.

Metric	Jun 1997	Jun 1998	Jun 1999	Jun 2000	Jun 2001	Jun 2002	Jun 2003	Jun 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	170.00K	-	1.53M	21.25M	47.54M	44.64M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.45M	19.99M	-	-
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-4.60M	-3.44M	-3.62M	-1.93M	-2.88M	-1.89M	-2.87M	-6.95M	-10.41M	-13.01M	-17.89M	-17.22M	-22.59M	-12.77M	2.57M	-6.28M
Net Income	-37.00K	-398.00K	-958.00K	-1.60M	-2.52M	-3.73M	-17.80M	-6.87M	-13.87M	-16.44M	-13.36M	-13.60M	-3.01M	-7.82M	4.68M	-5.16M	1.84M	-2.18M	-659.00K	-2.79M	-7.05M	-9.89M	-12.78M	-18.11M	-17.35M	-23.71M	-16.05M	-436.00K	-9.74M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.49	0.19	-0.21	0.17	-0.22	-0.06	-	-	-	-	-0.76	-0.67	-0.90	-0.60	-0.02	-0.34
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.49M	2.08M	579.00K	357.00K	256.00K	472.00K	1.94M	5.01M	5.61M	5.11M	4.98M	3.53M	56.00K	307.00K	250.00K

Balance Sheet (Annual)

Figures in USD.

Metric	Sep 1996	Jun 1997	Jun 1998	Jun 1999	Jun 2000	Jun 2001	Jun 2002	Jun 2003	Jun 2004	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Sep 2023	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.99M	5.35M	2.37M	1.75M	2.37M	1.02M	3.97M	28.40M	22.95M	14.15M	31.42M	22.41M	26.94M	19.98M	26.86M	44.95M	70.55M
Total Equity	0	-37.00K	-435.00K	242.00K	47.00K	9.79M	6.07M	698.00K	20.45M	16.65M	11.08M	1.27M	14.15M	3.05M	406.00K	-4.92M	-119.00K	-4.96M	-1.46M	613.00K	548.00K	3.57M	26.76M	21.31M	11.88M	29.07M	15.77M	-2.57M	9.58M	-11.62M	-5.87M	35.47M
Cash & Equivalents	0	-	-	-	-	-	-	-	-	-	-	-	-	-	685.00K	5.95M	5.30M	2.30M	1.66M	2.31M	942.00K	3.93M	28.26M	22.78M	13.65M	30.34M	21.10M	23.77M	-	13.27M	26.63M	36.79M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24.90M	-	30.93M	19.34M	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.92M	5.47M	7.32M	3.21M	1.76M	471.00K	402.00K	1.64M	1.64M	2.27M	2.35M	6.64M	29.51M	-	38.49M	50.82M	35.08M
Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.92M	5.47M	7.32M	3.21M	1.76M	471.00K	402.00K	1.64M	1.64M	2.27M	2.35M	1.65M	4.61M	-	7.55M	6.92M	10.52M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-1.93M	-3.23M	-2.99M	-2.21M	-1.70M	-2.12M	-3.64M	-7.83M	-9.06M	-15.60M	-14.22M	-18.06M	-17.14M	26.98M	-12.47M
Investing Cash Flow	-	0	0	0	0	0	0	0	-	-	-	-	-	-	-
Financing Cash Flow	7.19M	2.57M	0	1.57M	2.34M	5.11M	27.98M	2.35M	-71.00K	32.29M	4.98M	20.73M	6.64M	-13.62M	22.63M
Capital Expenditure	-	-0	-0	-0	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow	-	-3.23M	-2.99M	-2.21M	-	-	-	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Jun 1997	Jun 1998	Jun 1999	Jun 2000	Jun 2001	Jun 2002	Jun 2003	Jun 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	94.4%	94.1%	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10,520.6%	-	-1,471.6%	-60.1%	5.4%	-14.1%
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10,652.4%	-	-1,544.9%	-75.5%	-0.9%	-21.8%
ROE %	100.0%	91.5%	-395.9%	-3,414.9%	-25.8%	-61.5%	-2,549.4%	-33.6%	-125.2%	-1,296.5%	-94.4%	-445.5%	-741.9%	158.8%	-3,937.0%	104.2%	-126.8%	-355.0%	-120.3%	-78.1%	-26.3%	-46.4%	-107.6%	-62.3%	-110.0%	923.1%	138.1%	7.4%	-27.5%
ROCE %	-	-	-	-	-	-	-	-	-	-	-	-	-	93.5%	2,865.0%	73.0%	132.7%	-469.3%	-344.9%	-80.4%	-26.0%	-48.8%	-109.5%	-61.5%	-83.0%	-101.2%	-66.1%	6.8%	-10.5%

Shareholding Pattern

Insiders

14.46%

Institutions

54.29%

Public Float

63.47%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Rosalind Advisors, Inc.	8.34%	2.91M	$32.46M
2	Southpoint Capital Advisors Lp	7.87%	2.74M	$30.63M
3	Solas Capital Management, LLC	7.12%	2.48M	$27.70M
4	AIGH Capital Management LLC	5.68%	1.98M	$22.11M
5	Blackrock Inc.	3.92%	1.37M	$15.27M
6	Vanguard Capital Management LLC	2.57%	897.14K	$10.01M
7	AWM Investment Company, Inc.	2.06%	720.13K	$8.04M
8	Geode Capital Management, LLC	1.07%	371.74K	$4.15M
9	State Street Corporation	1.03%	359.06K	$4.01M
10	Potomac Capital Management, Inc.	0.64%	224.40K	$2.50M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FENC

Google News Mon, 13 Jul 2026

Understanding the Setup: (FENC) and Scalable Risk - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOVzVCU01hc05iSFVsNjZOWlNOMWFEQm04Ymh5TDJhNVlGY1JFTHdXSklydDVTNHRGTGg3NlZPMDc0b2ZPTGtiNGdnejZDM0R6VnBzRFYyUXp0VnJvMm8wTjV4ZzlSYTdPTVhfZ0FHOHUzbWQ0MXVCeGtKWWlWaDhtckZtd2d0bGI4NUNuMT…

Google News hu, 25 Jun 2026

FENC Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE8tOGFBM3FWdG96c2tVcWVwWnZIOE1WS0R4WktobEdLd25JZzFZYnJtQkEwNGU4T3FrMnM3dFM3ZW8weDlrMHk5a19td20wXy1pLWF3UEpyNUNYVk1OUi05cHVReXQxQ1JUZWQ4d254VldkS1RUSEE1TXJB?oc=5" target="_blank">FEN…

Google News Wed, 01 Jul 2026

Fennec (NASDAQ: FENC) Chief Strategy Officer receives 156-share stock award - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQa1YycGF1VHNwb1RqODEtcUJNYlpTeGFsRmhVeXdqalFaNW1yMUsyVlI5Wk11c1o4eEwzN2pBZkZPYzRYSkM2THM2cFBfVGJ1LWtMOElyVTVjWFUyQy1maFZHZFNYUk9BTkdoTW5RTUthVXNUc1ptVVlWbXM2RWtqUjlQNE1OY3hHZXEtX2…

Google News Mon, 06 Jul 2026

Is the Options Market Predicting a Spike in Adherex Technologies Stock? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQQ2JqNWo1c2c4N2VqbzdiUHNDZXNxYlphemF5clBTQy1MLUZSbE5FYWU0eTVqZmxnRmJac1pUcV8wVl9LMXRrSmI3WUNhWl9jREdiWW14alBrd3FWcGlzM0xkWS05OGJmd1hqbXJpN2lVSUtaa3YzOHJiU2FXQlliMGJxUGtGZk5rUkl1Rn…

Google News hu, 14 May 2026

FENNEC PHARMACEUTICALS ($FENC) Releases Q1 2026 Earnings - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQQXFjbGRnV1pYUzNBOHI1a2E2elFMVUxqOExERmdOckVmY1RJZ3dBZjlJazV1YXJkUkd1dmtnYW1zRzlLT1ZUN3VBYWlzV1pyLVpuQXBReGFEeFhiTzg0aDVqTFJtYU5WX1FMdVptTUZ6alVYTDgyYzRrR2ttX3lQSlR0N0RGN1ZSWnRydH…

Google News Sun, 17 May 2026

We're Not Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPckhUVU1hY2N3cFdlYmtlbnJUdXh5RUlvc2NtNzJxLW5DVTNMNkxxaGc5bG04ejUzUlItR24za3BMU3JiUkQ5MC0xVFF2dXhTQzNtbTQxbmRqeEZZN2J0QW9KczdtUi1CdmlrTnFVeWJHcVpTMVU4dUsyS3NlV1pWMU5zZ3FSZHdELVhTSH…

FENC — Frequently Asked Questions

What is the current share price of Fennec Pharmaceuticals Inc. (FENC)?

As of 2026-07-15 16:51 PDT, Fennec Pharmaceuticals Inc. (FENC) trades at $10.60 on NasdaqCM. Its 52-week range is $5.77 to $11.16.

What is the market capitalisation of FENC?

Fennec Pharmaceuticals Inc. (FENC) has a market capitalisation of $368.21M on NasdaqCM.

What is the P/E ratio of FENC?

FENC trades at a trailing price-to-earnings (P/E) ratio of -35.33. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 10.23.

What is the return on equity (ROE) of FENC?

FENC has a return on equity (ROE) of -52.68%. Its return on capital employed (ROCE) is -10.46%.

Is FENC a good stock to buy?

This page provides a data-driven analysis of Fennec Pharmaceuticals Inc. (FENC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Fennec Pharmaceuticals Inc. FENC R2K

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Understanding the Setup: (FENC) and Scalable Risk - Stock Traders Daily

FENC Forecast — Price Target — Prediction for 2027 - TradingView

Fennec (NASDAQ: FENC) Chief Strategy Officer receives 156-share stock award - Stock Titan

Is the Options Market Predicting a Spike in Adherex Technologies Stock? - Yahoo Finance

FENNEC PHARMACEUTICALS ($FENC) Releases Q1 2026 Earnings - Quiver Quantitative

We're Not Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn - simplywall.st

FENC — Frequently Asked Questions

What is the current share price of Fennec Pharmaceuticals Inc. (FENC)?

What is the market capitalisation of FENC?

What is the P/E ratio of FENC?

What is the return on equity (ROE) of FENC?

Is FENC a good stock to buy?

Explore More